The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EORTC CLTF 2018 | First-in-human study of IPH4102 for relapsed cutaneous T-cell lymphoma
Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, speaks at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, on the progress of a new monoclonal antibody, IPH4102, being trialed for the first time in humans (NCT02593045). Prof. Bagot describes the results of the KIR3DL2-targeting antibody currently in Phase I of development, highlighting the plan to conduct the drug’s Phase II clinical trial in 2019 on patients of Sézary syndrome, mycosis fungoides and nodal peripheral T-cell lymphoma.
